Compare XYF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | MGNX |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.4M | 220.6M |
| IPO Year | 2018 | 2013 |
| Metric | XYF | MGNX |
|---|---|---|
| Price | $4.89 | $4.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 133.3K | ★ 1.3M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.30 | $1.19 |
| 52 Week High | $20.36 | $4.64 |
| Indicator | XYF | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 66.06 |
| Support Level | $4.86 | $1.48 |
| Resistance Level | $5.12 | N/A |
| Average True Range (ATR) | 0.31 | 0.33 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 67.33 | 85.75 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.